Jeff Yass’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Jeff Yass’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-15,124	Closed	-$37K	–	11008
2018 Q1	$36K	Sell	15,124 -18,618	-55%	-$47K	﹤0.01%	9048
2017 Q4	$81K	Buy	33,742 +20,646	+158%	+$57.1K	﹤0.01%	8771
2017 Q3	$41K	Buy	+13,096	New	+$42K	﹤0.01%	8579
2016 Q4	–	Sell	-2,018	Closed	-$13K	–	10630
2016 Q3	$13K	Sell	2,018 -8,824	-81%	-$54.4K	﹤0.01%	8281
2016 Q2	$49K	Buy	10,842 +7,904	+269%	+$51.6K	﹤0.01%	8249
2016 Q1	$31K	Sell	2,938 -1,514	-34%	-$30.1K	﹤0.01%	8763
2015 Q4	$131K	Sell	4,452 -435	-9%	-$13.2K	﹤0.01%	8748
2015 Q3	$154K	Sell	4,887 -3,411	-41%	-$163K	﹤0.01%	8903
2015 Q2	$491K	Buy	+8,298	New	+$585K	﹤0.01%	7672
2014 Q3	–	Sell	-9,514	Closed	-$749K	–	10361
2014 Q2	$854K	Buy	+9,514	New	+$583K	﹤0.01%	6378

Other funds holding PTX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

MFGP

Marshall Financial Group (Pennsylvania) Doylestown, Pennsylvania $364M AUM 12.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's PTX Position: Q2 2018 in Review

Jeff Yass sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2018, closing a stake of 15,124 shares — an estimated $37K sold.

Jeff Yass first reported a position in PTX in Q2 2014 and held it in 10 quarters. The position peaked at $854K in Q2 2014. 29 funds tracked by Wall St. Rank hold PTX as of Q2 2018.

Jeff Yass reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2018 after selling out during the quarter.
Jeff Yass sold 15,124 Pernix Therapeutics Holdings, Inc. shares in Q2 2018, an estimated $37K.
Jeff Yass first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2014 and held it in 10 quarters.
Jeff Yass's Pernix Therapeutics Holdings, Inc. position peaked at $854K in Q2 2014.
29 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2018.

Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.